A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

NCT04158700 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped The withdrawal is due to a strategic realignment and is not related to any particular safety or efficacy concern.

Conditions

Interventions

Sponsor

Eli Lilly and Company

Collaborators